Lyka Labs (BOM:500259) Earnings per Share (Diluted) : ₹-0.80 (TTM As of Mar. 2024)

View and export this data going back to 1992. Start your Free Trial

What is Lyka Labs Earnings per Share (Diluted)?

Lyka Labs's Earnings per Share (Diluted) for the three months ended in Mar. 2024 was ₹-0.60. Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2024 was ₹-0.80.

Lyka Labs's EPS (Basic) for the three months ended in Mar. 2024 was ₹-0.60. Its EPS (Basic) for the trailing twelve months (TTM) ended in Mar. 2024 was ₹-0.80.

Lyka Labs's EPS without NRI for the three months ended in Mar. 2024 was ₹-0.60. Its EPS without NRI for the trailing twelve months (TTM) ended in Mar. 2024 was ₹-0.69.

During the past 3 years, the average EPS without NRIGrowth Rate was 42.80% per year.

During the past 13 years, Lyka Labs's highest 3-Year average EPS without NRI Growth Rate was 53.00% per year. The lowest was -166.50% per year. And the median was 14.50% per year.

Lyka Labs Earnings per Share (Diluted) Historical Data

The historical data trend for Lyka Labs's Earnings per Share (Diluted) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Lyka Labs Earnings per Share (Diluted) Chart

Lyka Labs Annual Data

Trend

Jun14

Jun15

Mar17

Mar18

Mar19

Mar20

Mar21

Mar22

Mar23

Mar24

Earnings per Share (Diluted)

Get a 7-Day Free Trial

-21.29

-4.07

13.57

-4.63

-0.79

Lyka Labs Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Earnings per Share (Diluted)	Get a 7-Day Free Trial															-1.04	-0.57	-0.16	0.53	-0.60

Competitive Comparison of Lyka Labs's Earnings per Share (Diluted)

For the Biotechnology subindustry, Lyka Labs's PE Ratio, along with its competitors' market caps and PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Lyka Labs's PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Lyka Labs's PE Ratio distribution charts can be found below:

* The bar in red indicates where Lyka Labs's PE Ratio falls into.

Lyka Labs Earnings per Share (Diluted) Calculation

Earnings Per Share (EPS) is the amount of earnings per outstanding share of the company's stock. In calculating earnings per share, the dividends of preferred stocks need to subtracted from the total net income first.

Lyka Labs's Earnings Per Share (Diluted) for the fiscal year that ended in Mar. 2024 is calculated as

Diluted Earnings Per Share (A: Mar. 2024 )	=	(Net Income	-	Preferred Dividends)	/	Shares Outstanding (Diluted Average)
	=	(-24.892	-	0)	/	31.509
	=	-0.79

Lyka Labs's Earnings Per Share (Diluted) for the quarter that ended in Mar. 2024 is calculated as

Diluted Earnings Per Share (Q: Mar. 2024 )	=	(Net Income	-	Preferred Dividends	/	Shares Outstanding (Diluted Average)
	=	(-19.37	-	0)	/	38.846
	=	-0.50

Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹-0.80

Companies also reported diluted shares in their financial reports. Diluted shares include the shares of convertibles or warrants outstanding.

Lyka Labs (BOM:500259) Earnings per Share (Diluted) Explanation

Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.

Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.

Lyka Labs Earnings per Share (Diluted) Related Terms

Thank you for viewing the detailed overview of Lyka Labs's Earnings per Share (Diluted) provided by GuruFocus.com. Please click on the following links to see related term pages.

Lyka Labs (BOM:500259) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Lyka Labs Ltd (BOM:500259) » Definitions » Earnings per Share (Diluted)

Comparable Companies

Traded in Other Exchanges

LYKALABS:India

Address

30, Forjett Street, Near Bhatia Hospital, Ground floor, Spencer Building (Block B & C), Grant Road (West), Mumbai, MH, IND, 400036

Website

http://www.lykalabs.com

Lyka Labs Ltd is an Indian biotechnology company. It mainly engages in the development of specialized formulations. The Company is engaged in only one segment viz. pharmaceuticals. The Company has presence in Domestic as well as International markets. The commercialized formulations of the company consist of hair care, anti-aging, acne management, skin lightening, face washes, sunscreens, facial scrubs, and others. It has developed a varied drug delivery system for topical steroids, painkillers, anti-fungal, and other emollients as well as liquid injectables, lyophilized injectables in the anti-bacterial, antifungal segment. The company also manufactures proton pump inhibitors, antibiotics, antifungals, steroids, etc. The majority of the company's revenue comes from India.

Lyka Labs (BOM:500259) Headlines

No Headlines